SEC Form 4 · accession 0001209191-18-021389
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Pontifax (Cayman) IV L.P.
10% Owner
Pontifax (China) IV L.P.
10% Owner
Pontifax (Israel) IV, L.P.
10% Owner
Pontifax IV GP L.P.
10% Owner
Period of report
Mar 21, 2018
Accepted (ET)
Mar 23, 2018 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 21, 2018 | P | 1,585 | $7.55 | A | 383,103 | I | By Pontifax Investment Fund |
| Common StockF2 | Mar 21, 2018 | P | 3,255 | $7.55 | A | 786,919 | I | By Pontifax Investment Fund |
| Common StockF3 | Mar 21, 2018 | P | 1,760 | $7.55 | A | 425,463 | I | By Pontifax Investment Fund |
| Common StockF1 | Mar 22, 2018 | P | 1,441 | $8.00 | A | 384,544 | I | By Pontifax Investment Fund |
| Common StockF2 | Mar 22, 2018 | P | 2,959 | $8.00 | A | 789,878 | I | By Pontifax Investment Fund |
| Common StockF3 | Mar 22, 2018 | P | 1,600 | $8.00 | A | 427,063 | I | By Pontifax Investment Fund |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- F2Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
- F3Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.